Leblon Delienne Joins LEXON at BOW to Expand Its Global Reach
8.9.2026 14:36:00 CEST | Business Wire | Press release
The French sculpture atelier extends the group’s expertise from everyday design to collectible art
BOW (Brands of Wonder), the international brand group behind French design brand LEXON, today announced the acquisition of Leblon Delienne, the French sculpture atelier known for transforming pop culture icons into collectible art and design objects. The move pairs the atelier’s distinctive French craftsmanship and licensed collections with BOW’s international reach and digital expertise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908641342/en/

Leblon Delienne Joins LEXON at BOW
Juliette de Blegiers, who acquired the company in 2018, will remain a minority shareholder in Leblon Delienne and continue working alongside BOW founder Boris Brault and the atelier’s teams.
For more than 40 years, Leblon Delienne has brought iconic characters to life through sculptures, figurines, furniture, and art and design objects, primarily in limited, numbered editions. Its licensed collections feature characters from Disney, Warner Bros., Peanuts, Playmobil, and Sanrio. The atelier also collaborates with artists, designers, interior designers, and luxury brands on exceptional custom commissions.
Its artisans craft sculptures at the atelier in Neufchâtel-en-Bray, Normandy. Leblon Delienne holds France’s Entreprise du Patrimoine Vivant (EPV, or “Living Heritage Company”) designation, an official distinction overseen by the French Ministry of the Economy and awarded to businesses with rare and exceptional know-how.
“Leblon Delienne is a truly distinctive atelier, transforming universally recognized characters into objects of desire,” said Boris Brault, founder and president of BOW. “It brings together everything that inspires me: history, emotion, craftsmanship, and a vision at the intersection of art, design, and pop culture.
With the global collectibles market flourishing, driven by a growing adult audience, Leblon Delienne and BOW are a natural creative and strategic fit. This marks a new step in our ambition to build a group of complementary design and art brands for the home, each with its own distinctive identity. Through LEXON, we have developed recognized expertise in creating licensed collections and collaborations with renowned partners around everyday design objects. With Leblon Delienne, we are now extending that approach to collectible art objects and strengthening our licensing portfolio.
Our aim is not to change Leblon Delienne, but to preserve its soul and give it the resources to go further: developing new collections, creating compelling collaborations, accelerating its digital growth, and expanding its international reach. I am especially pleased that Juliette will remain by my side as we begin this new chapter with our teams.”
Since joining BOW in 2018, LEXON has grown its global product sales nearly fivefold. International markets now account for 80% of its business, and the United States is its largest e-commerce market. LEXON has earned more than 250 international design awards and is sold in 90 countries through more than 9,000 retail locations, selling millions of products each year.
LEXON’s Balloon Dog collaboration with Jeff Koons, imagined with The Broad in Los Angeles, illustrates that combination of creative ambition and global reach. Its first edition attracted thousands of collectors worldwide in less than a year.
Leblon Delienne’s creative collaborators include Jean-Charles de Castelbajac, Eugeni Quitllet, and José Lévy. Both Quitllet and Lévy have also designed for LEXON, reflecting the two brands’ shared interest in design, emotional connection, and fresh interpretations of familiar objects and cultural icons.
BOW will support Leblon Delienne with its digital platforms and expertise in selling art and collectibles online, bringing its creations to new audiences and deepening relationships with collectors.
The group plans to develop new art licensing partnerships and exclusive sculptures while expanding international distribution. The ambition is to make Leblon Delienne a destination for collectors and a leading global name in collectible sculpture. Its Normandy atelier, artisans, and teams will remain at the heart of its creative work.
“Since 2018, we have worked with our teams to preserve and pass on our atelier’s craftsmanship while giving our creations a distinctly contemporary voice,” said Juliette de Blegiers, Chief Brands & Collaborations Officer at BOW. “We have maintained our expertise in the classic comic-book figurines that made Leblon Delienne’s name in the 1980s, while creating new collectible objects that reflect today’s culture.
What connects us with BOW is a shared commitment to artistic creation and to making timeless, increasingly sought-after objects. Leblon Delienne has enormous potential. The group will bring a product-focused approach, digital capabilities, and global distribution that complement our own strengths. I am proud of this partnership, which allows us to continue our brand’s story by drawing on each other’s strengths and a shared ambition.
I am also delighted to continue this journey alongside Boris Brault and write this next chapter together.”
ABOUT LEBLON DELIENNE
Founded in 1985, Leblon Delienne is a French sculpture atelier that reinterprets pop culture icons through figurines, sculptures, furniture, and design objects. Recognized with France’s Living Heritage Company designation, the atelier designs its collections in Neufchâtel-en-Bray, Normandy, France.
www.leblon-delienne.com
ABOUT BOW
Founded by Boris Brault, BOW (Brands of Wonder) is an entrepreneur-led international group that develops brands at the intersection of design, art, innovation, and emotional connection. Its brands include French design brand LEXON. The group combines expertise in product development, international distribution, and e-commerce.
www.group-bow.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260908641342/en/






Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom